TherapeuticsMD Inc.

NASDAQ: TXMD · Real-Time Price · USD
1.41
0.17 (13.71%)
At close: May 01, 2025, 3:58 PM
1.45
2.86%
After-hours: May 01, 2025, 06:44 PM EDT

Company Description

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States.

The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.

It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands.

The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.

TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TherapeuticsMD Inc.
TherapeuticsMD Inc. logo
Country United States
IPO Date May 9, 2007
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1
CEO Marlan D. Walker J.D.

Contact Details

Address:
951 Yamato Road
Boca Raton, Florida
United States
Website https://www.therapeuticsmd.com

Stock Details

Ticker Symbol TXMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000025743
CUSIP Number 88338N206
ISIN Number US88338N2062
Employer ID 87-0233535
SIC Code 2834

Key Executives

Name Position
Marlan D. Walker J.D. Chief Executive Officer
Douglas Steelman Vice President of Market Access
Governor Thomas G. Thompson Executive Chairman
Joseph A. Ziegler Principal Financial & Accounting Officer

Latest SEC Filings

Date Type Title
Apr 30, 2025 10-K/A [Amend] Annual Report
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 10, 2025 4 Filing
Apr 09, 2025 8-K Current Report
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Feb 20, 2025 4 Filing
Feb 20, 2025 4 Filing
Feb 20, 2025 4 Filing